There was an article out of Boston on the 19th of November about who would be the losers if CMS rendered the decision we have just seen. The big losers are Organogenesis and Shire pharmaceuticals. Apligraf and Dermagraft simply have so much wastage with their product they will have to make around a 35 to 40% price cut. The CMS decision is a game changer for MImedex.
I talked about this very article a few threads down and hinted at this months ago. Organogensis, located in MA, lobbied CMS hard. Judging by the multiple comments, the PMA products were fighting tooth and nail. Another interesting thing that came out is that CMS does not care if the products are PMA, BLA or 361 from a reimbursement standpoint.